Topical Use of Vancomycin in Reducing Sternal Wound Infection in Cardiac Surgery (SWI Trial) (SWI)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02374853|
Recruitment Status : Terminated (the preliminary analysis of study result did not show significant benefit that was anticipate)
First Posted : March 2, 2015
Last Update Posted : April 25, 2019
|Condition or disease||Intervention/treatment||Phase|
|INFECTION||Drug: Vancomycin Other: No Vancomycin||Phase 2|
During open-heart surgery, an incision is made along the chest and the sternum (breastbone) is divided. The sternum is held open throughout the surgery so that the doctors can reach the heart. Sternal wound infection is an uncommon but serious complication of cardiac surgery that occurs when an infection develops at this site of entry. Sternal wound infections are associated with increased hospital stays, subsequent surgical procedures, and higher mortality rates.
The purpose of this research is to determine if using the antibiotic vancomycin as a preventative topical (on the surface of the skin) treatment during open-heart surgery will reduce the risk of developing a sternal wound infection. The results of this study could provide important information to guide new standards of practice in cardiac surgery. The ultimate goal of this research project is to improve patient care by reducing the number of sternal wound infections at our hospital.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||894 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||Topical Use of Vancomycin in Reducing Sternal Wound Infection in Cardiac Surgery (SWI Trial)|
|Study Start Date :||March 2015|
|Actual Primary Completion Date :||April 2019|
|Actual Study Completion Date :||April 2019|
During open heart surgery, patients will have a 4 x 8 inch piece of sterile gauze covering each side of the divided sternum. The gauze will be soaked in the following solution: 5 g vancomycin dissolved in 50 mL sterile water
Topical prophylactic antibiotic
Other Name: Vancomycin Hydrochloride
Placebo Comparator: Control
During open heart surgery, patients will have a 4 x 8 inch piece of sterile gauze covering each side of the divided sternum. The gauze will be soaked in 50 mL sterile water. No Vancomycin
Other: No Vancomycin
Placebo: Sterile water. No Vancomycin.
Other Name: Sterile water
- Incidence of sternal wound infection [ Time Frame: 3 months postoperative ]The primary endpoint of this trial is the incidence of sternal wound infection at 3 months postoperative. This includes superficial incisional, deep incisional, and organ/space surgical site infections.
- Incidence of sternal wound infection [ Time Frame: 1 year postoperative ]
- Hospitalization [ Time Frame: 1 year postoperative ]Duration of index hospitalization and subsequent re-admissions due to sternal wound infection.
- Use of prophylactic antibiotics [ Time Frame: 1 year postoperative ]
- Cost analysis for sternal wound infection treatment [ Time Frame: 1 year postoperative ]
- Adverse events [ Time Frame: 1 year postoperative ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02374853
|Principal Investigator:||Abbas Khani-Hanjani, MD||University of Alberta|